Rivory L P
Sydney Cancer Centre, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia.
Ann N Y Acad Sci. 2000;922:205-15. doi: 10.1111/j.1749-6632.2000.tb07039.x.
Irinotecan (CPT-11) is a semi-synthetic camptothecin with a broad spectrum of clinical activity. It is a prodrug that is cleaved by esterases to the potent topoisomerase I poison, SN-38. In humans, this activation is relatively inefficient, but this may result in a more protracted formation of SN-38 lactone. Some intratumoral activation may also occur, but the significance of this process is uncertain. CPT-11 is metabolized by cytochrome P450 3A to yield a number of comparatively inactive compounds. SN-38 is glucurono-conjugated in the liver, and this metabolite, although inactive, may participate in the enterohepatic cycling of SN-38 after hydrolysis in the intestinal lumen. Overall, the production of SN-38 from CPT-11 is the result of the complex interplay of several metabolic pathways and the source of considerable interpatient variability.
伊立替康(CPT - 11)是一种具有广泛临床活性的半合成喜树碱。它是一种前体药物,可被酯酶裂解为强效的拓扑异构酶I毒药SN - 38。在人体内,这种激活相对低效,但这可能导致SN - 38内酯的形成更为持久。肿瘤内也可能发生一些激活,但该过程的意义尚不确定。CPT - 11通过细胞色素P450 3A代谢产生许多相对无活性的化合物。SN - 38在肝脏中与葡萄糖醛酸结合,这种代谢产物虽然无活性,但在肠腔内水解后可能参与SN - 38的肠肝循环。总体而言,CPT - 11产生SN - 38是多种代谢途径复杂相互作用的结果,也是患者间显著差异的来源。